Stock PPBT PURPLE BIOTECH LTD
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Purple Biotech Ltd Nasdaq

Equities

PPBT

US74638P1093

Market Closed - Nasdaq
Other stock markets
 21:30:00 17/05/2024 BST 		5-day change 1st Jan Change
0.554 USD +10.34% Intraday chart for Purple Biotech Ltd +4.67% -28.97%
04-25 Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting CI
03-14 Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
Purple Biotech Ltd. Announces Executive Changes
Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Purple Biotech Closes $5 Million Registered Direct Offering
Purple Biotech Reports Potential Biomarker Data Support CM24?s Mechanism of Action
Purple Biotech Reports Positive Interim Results From Study of NT219 Cancer Treatment Candidate
Purple Biotech Ltd. Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
Purple Biotech Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Purple Biotech Reports Results of Dose Escalation Trial of CM24 in Advanced Pancreatic Cancer; Shares Fall
Purple Biotech Ltd. Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
Top Premarket Gainers
Purple Biotech Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Purple Biotech : Launches Trial of Monoclonal Antibody CM24 in Advanced Cancer Patients
Purple Biotech : Commences Phase 1b/2 Clinical Trial of CM24 in Multiple Advanced Cancers
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PPBT Stock
  4. PPBT Stock
  5. News Purple Biotech Ltd
  6. Other languages